METHODS: Patients received chemotherapy comprising epirubicin and cyclophosphamide pre- or postoperatively. AE were evaluated using 4 questionnaires:PRO-CTCAE, CTCAE, the European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC-QLQ-30), and Hospital Anxiety and Depression Scale (HADS) after 1, 2, and 3 courses of chemotherapy.
RESULTS: Forty-two patients were registered. Regarding the recognition of psychological symptoms, such as fatigue, anxiety, and discouragement, and subjective symptoms, including heart palpitations and shortness of breath, PRO using PRO-CTCAE was significantly higher than medical provider-recognized outcomes using CTCAE. Concerning the recognition of regimen-specific symptoms, such as vomiting, nausea, and decreased appetite, medical provider- recognized outcomes were the same or higher than PRO. In QLQ-C30, the physical and role functions, fatigue and dyspnea significantly worsened after 2 and 3 courses of chemotherapy. J. Med. Invest. 71 : 82-91, February, 2024.
方法:患者术前或术后接受包含表柔比星和环磷酰胺的化疗。AE使用4份问卷进行评估:PRO-CTCAE,CTCAE,欧洲癌症研究和治疗组织-生活质量问卷(EORTC-QLQ-30),化疗1、2和3个疗程后,医院焦虑和抑郁量表(HADS)。
结果:登记了42例患者。关于心理症状的识别,比如疲劳,焦虑,和沮丧,和主观症状,包括心悸和呼吸急促,使用PRO-CTCAE的PRO显着高于使用CTCAE的医疗提供者认可的结果。关于方案特异性症状的识别,比如呕吐,恶心,食欲下降,医疗提供者认可的结果与PRO相同或高于PRO。在QLQ-C30中,身体和角色功能,2个和3个疗程的化疗后,疲劳和呼吸困难明显恶化。J.Med.投资。71:82-91,二月,2024.